World Conference on Lung Cancer 2025 MEDSIR drives innovation in lung cancer with active brain metastases and promotes global collaboration at WCLC 2025

• The company has presented the promising REPOSE study, which evaluates the efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) with ROS1 gene mutation and active brain metastases.

  
  

• The ISTs Innovation Forum, an exclusive event organized by MEDSIR, brought together international leaders to co-design high-impact, investigator-driven oncology clinical trials and explore the opportunities offered by Artificial Intelligence in research.

• As part of the congress, MEDSIR reaffirmed its global leadership and commitment to independent oncology research, highlighting the value of its international network of collaborators and strategic alliances for greater global impact.

Barcelona, September 9, 2025 – The international medical research company MEDSIR reaffirms its ongoing commitment to innovation, addressing unmet medical needs, and promoting independent oncology research worldwide through its participation in the World Conference on Lung Cancer (WCLC) 2025. During the congress, MEDSIR shared significant advances and led a strategic event focused on independent clinical research.

MEDSIR team during WCLC 2025

REPOSE Study: New Perspectives for ROS1+ Lung Cancer with Brain Metastases

MEDSIR presented the design of the REPOSE study (NCT06315010) in poster format—an international, multicenter, open-label, phase II clinical trial. This study evaluates the efficacy of repotrectinib in patients with non-small cell lung cancer (NSCLC) who are ROS1-positive and have active brain metastases. The primary objective is to assess the treatment’s effectiveness in reducing brain tumor lesions—an area of unmet medical need.

“The REPOSE study is a testament to how independent research can address critical challenges in oncology, such as brain metastases in lung cancer,” said Alicia García, Scientific Director at MEDSIR. “We are excited to share this study, which opens a new path for ROS1-mutated patients and represents a step forward in precision medicine for lung cancer.”

Dr. Thorsten Füreder, PI of REPOSE study, with the poster during WCLC 2025

ISTs Innovation Forum: Designing the Future of Clinical Trials

As part of its commitment to international collaboration and innovation, MEDSIR hosted the exclusive ISTs Innovation Forum at the Renaissance Barcelona Fira Hotel. The event brought together leading global oncology experts and the next generation of changemakers to co-design high-impact, investigator-driven clinical trials, while also exploring the crucial role of Artificial Intelligence in optimizing cancer research.

The forum featured high-level mentors such as Dr. Alfredo Addeo (Switzerland), Dr. Arsela Prelaj (Italy), Dr. Patrick Forde (Ireland), Dr. Kaushal Parikh (USA), and Dr. Stephanie Saw (Singapore), offering a dynamic experience and a unique opportunity to accelerate innovation in lung cancer clinical trials.

Advancing Independent Oncology Research Worldwide

Additionally, as a member of the I3LUNG project consortium, funded by the European Commission, MEDSIR presented results that promote the application of artificial intelligence and multimodal medicine in lung cancer. Posters showcased findings on the potential of voice analysis for cancer detection and PD-L1 expression prediction from histological images. A separate oral session introduced a clinical decision support system designed to predict immunotherapy efficacy.

“Our success at WCLC 2025 demonstrates the strength of our research model, based on scientific excellence, international cooperation, and operational agility,” said Giulia Raimondi, Strategic Research Development Chief at MEDSIR. “This allows us to foster collaboration among key players in the pharmaceutical and biotech industries, as well as researchers worldwide, to make a real impact on patients. We continue to expand our reach in thoracic tumors with disruptive solutions and by connecting industry leaders to address unmet clinical needs.”

MEDSIR reiterates its commitment to excellence in oncology research and the relentless pursuit of solutions for patients’ unmet needs—a philosophy reflected in its active participation in international congresses like WCLC 2025. With strategic headquarters in Spain and the United States, the company has built a global network of over 600 researchers, conducting 65 clinical trials across more than 200 centers in 14 countries.

For more information about MEDSIR’s activities at WCLC 2025 and its research programs, visit www.medsir.org

ABOUT MEDSIR 

Established in 2012, MEDSIR prides itself on working closely with its strategic partners to drive innovation in oncology research. Operating in Spain and the United States, the company provides end-to-end clinical trial management, from study design to publication, with an extensive global network of experts and integrated technology to streamline the process. The company offers proof-of-concept support and a strategic approach that enables research partners to benefit from the best of both worlds: industry clinical research and investigator-driven trials.     

With the aim of promoting independent research worldwide, MEDSIR has formed a strategic alliance with Oncoclínicas, the leading oncology group in Brazil, which offers outstanding research potential in South America.  

For further information: www.medsir.org